Rankings
▼
Calendar
ALNY (Alnylam Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
Mkt Cap
$43B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$3.7B
Net Income (TTM)
$314M
EPS (TTM)
$2.26
Free Cash Flow (TTM)
$465M
Gross Margin
81.7%
Op. Margin
13.5%
Net Margin
8.4%
FCF Margin
12.5%
P/S Ratio (TTM)
11.6x
P/E Ratio (TTM)
137.6x
YoY Rev Growth
+65.2%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$319M
$264M
-$150M
Q2 23
$319M
$233M
-$230M
Q3 23
$751M
$666M
$214M
Q4 23
$440M
$354M
-$116M
Q1 24
$494M
$428M
-$43M
Q2 24
$660M
$591M
$49M
Q3 24
$501M
$415M
-$77M
Q4 24
$593M
$490M
-$105M
Q1 25
$594M
$523M
$18M
Q2 25
$774M
$631M
-$16M
Q3 25
$1.2B
$1.1B
$368M
Q4 25
$1.1B
$829M
$132M
marketcaparena.com
Revenue Breakdown
ALNY
Alnylam Pharmaceuticals, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
37.8x
—
Q2 23
34.9x
—
Q3 23
25.0x
—
Q4 23
23.6x
—
Q1 24
21.5x
—
Q2 24
18.4x
—
Q3 24
20.6x
—
Q4 24
19.2x
—
Q1 25
18.4x
—
Q2 25
17.5x
—
Q3 25
13.4x
990.9x
Q4 25
11.6x
137.6x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$166M
-$180M
Q2 23
-$59M
-$75M
Q3 23
$359M
$342M
Q4 23
-$30M
-$45M
Q1 24
-$82M
-$94M
Q2 24
$124M
$116M
Q3 24
$44M
$40M
Q4 24
-$95M
-$104M
Q1 25
-$118M
-$127M
Q2 25
$154M
$139M
Q3 25
$325M
$313M
Q4 25
$164M
$140M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$14M
Q2 23
$16M
Q3 23
$17M
Q4 23
$15M
Q1 24
$13M
Q2 24
$8M
Q3 24
$4M
Q4 24
$9M
Q1 25
$9M
Q2 25
$14M
Q3 25
$12M
Q4 25
$23M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+49.7%
+30.3%
Q2 23
+41.8%
+31.7%
Q3 23
+184.0%
+2.7%
Q4 23
+31.2%
+6.2%
Q1 24
+54.8%
+14.6%
Q2 24
+107.0%
+11.4%
Q3 24
-33.3%
+7.7%
Q4 24
+34.9%
+25.6%
Q1 25
+20.2%
+7.1%
Q2 25
+17.3%
+29.2%
Q3 25
+149.3%
+52.5%
Q4 25
+84.9%
+38.2%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$40M
12.5%
Q2 23
$76M
23.8%
Q3 23
$64M
8.5%
Q4 23
$42M
9.6%
Q1 24
$45M
9.2%
Q2 24
$89M
13.5%
Q3 24
$46M
9.1%
Q4 24
$92M
15.5%
Q1 25
$57M
9.5%
Q2 25
$112M
14.4%
Q3 25
$108M
8.7%
Q4 25
$0
0.0%
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q1 23
$231M
$184M
—
Q2 23
$249M
$215M
—
Q3 23
$253M
$199M
—
Q4 23
$272M
$198M
—
Q1 24
$261M
$211M
—
Q2 24
$294M
$248M
—
Q3 24
$271M
$221M
—
Q4 24
$300M
$295M
—
Q1 25
$265M
$240M
—
Q2 25
$324M
$323M
—
Q3 25
$359M
$322M
—
Q4 25
$372M
—
$325M
marketcaparena.com
Revenue Segments
Product
Royalty
Givlaari
Onpattro
Quarter
Product
Royalty
Givlaari
Onpattro
Q2 23
$306M
$7M
—
—
Q1 24
$365M
—
$58M
$69M
Q1 25
$469M
—
$67M
$49M
Q2 25
$672M
—
$81M
$53M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$672M
$1.4B
$2.1B
Q2 23
$658M
$1.4B
$2.1B
Q3 23
$1.0B
$1.4B
$2.4B
Q4 23
$813M
$1.6B
$2.4B
Q1 24
$682M
$1.7B
$2.4B
Q2 24
$968M
$1.7B
$2.6B
Q3 24
$1.1B
$1.7B
$2.8B
Q4 24
$966M
$1.7B
$2.7B
Q1 25
$1.0B
$1.6B
$2.6B
Q2 25
$1.1B
$1.7B
$2.9B
Q3 25
$1.5B
$1.2B
$2.7B
Q4 25
$1.7B
$1.3B
$2.9B
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
124M
+0.7%
Q2 23
125M
+0.4%
Q3 23
131M
+5.4%
Q4 23
126M
-4.4%
Q1 24
126M
+0.4%
Q2 24
127M
+0.5%
Q3 24
129M
+1.5%
Q4 24
129M
+0.0%
Q1 25
130M
+0.8%
Q2 25
130M
+0.0%
Q3 25
137M
+5.9%
Q4 25
136M
-0.8%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$198K
256
FY 15
$111K
369
FY 16
$92K
514
FY 17
$120K
749
FY 18
$70K
1K
FY 19
$166K
1K
FY 20
$339K
1K
FY 21
$507K
2K
FY 22
$518K
2K
FY 23
$871K
2K
FY 24
$1M
2K
FY 25
$1M
3K
marketcaparena.com